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Lauryl gallate (antioxidant food additive E-312) prevents the formation of dimethylbenzanthracene-induced skin tumours in mice, and
kills, selectively, tumoral cells on established tumours. This results in total remission, after topical application of the compound on the
tumoral mass, without affecting the surrounding tissue.
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We have reported that triphenols such as gallic acid (3,4,5-
trihydroxybenzoic acid) and its esters (methyl, propyl (E-310),
octyl (E-311) and lauryl (E-312)) inhibit protein tyrosine kinases
(PTKs) (La ´zaro et al, 1995; Palacios et al, 2002). Similarly to other
PTK inhibitors such as genistein (Uckun et al, 1995), herbymicin
(Otani et al, 1993), staurosporin (Bossy-Wetzel et al, 1998),
tyrphostins (Burger et al, 1995), etc., they show an antiproliferative
effect on tumoral cell lines (Serrano et al, 1998). The most
hydrophobic of the alkyl gallates (octyl and lauryl) exhibit a
proapoptotic potency between 50 and 250 times higher than gallic
acid for the lines tested (Serrano et al, 1998). The study of lauryl
gallate (LG) on the pre-B cell lymphoma Wehi 231 line shows that
it inhibits PTKs both in crude extracts and whole cells, disrupts the
mitochondrial membrane potential, promotes the efflux of
cytochrome c to the cytosol, activates the cascade of caspases
and induces oligonucleosomal breakdown of DNA (Roy et al,
2000). Also these types of compounds seem to show a selectivity
for rapidly growing cells, opening the possibility of their study as
potential antitumoral agents (Serrano et al, 1998). Here, we report
that LG not only prevents the formation of chemically induced
skin tumours in mice but is also able to kill, selectively, tumoral
cells in established tumours.
MATERIALS AND METHODS
Chemicals
Lauryl gallate (Fluka), 7,12-dimethylbenzanthracene, phorbol
myristate acetate, dimethylsulphoxide, acetone and glycerol were
supplied by Sigma-Aldrich Quı ´mica (Spain).
Mice
IRC mice (6–8 weeks old) were from the Charles River
Laboratories (Saint Aubin les Elbeuf, Rouen, France). All
experiments involving ‘in vivo’ testing were carried out with
ethical committee approval and met the standards required by the
guidelines for the welfare of animals in experimental neoplasia
(Workman et al, 1998).
Prevention of tumour formation Thirty-two IRC mice were
individualised and subdivided into four groups (four
females and four males per group), as shown in Table 1.
The induction of the tumours was performed following the
protocol described (Segal et al, 1978) with a slight modification.
The solvent used was a mixture of dimethylsulphoxide and
glycerol (1:1), in which all the compounds were soluble.
After a single application of 25mg of 7,12-dimethylbenz[a]
anthracene (DMBA) in a volume of 20ml, and 15 days with-
out treatment, a solution of 5mg of phorbol-12-myristate-
13-acetate (PMA) with different doses of LG (Fluka) was
applied topically three times per week. The doses of LG were
0 (controls), 2.5, 10 and 50mg in a volume of 20ml per application.
After 6–7 weeks of treatment, tumours appeared on 90% of the
control mice, and the behaviour of LG was evaluated as shown in
Table 1.
Regression of established tumours Twenty-four individualised
mice were treated with a single application of 25mg of DMBA, and
after 15 days with no application of compounds, 5mg of PMA was
applied three times a week (6–7 weeks) until the tumour appeared.
The mice were subdivided into three different groups (LG 100, LG
250 and LG 500, four males and four females per group),
depending on the treatment dose after tumour formation. The
volume per application was 20ml, which was sufficient to cover the
whole tumour surface and was applied three times a week for a
period of 8 weeks.
Received 17 July 2002; revised 11 November 2002; accepted 25
November 2002
*Correspondence: Dr P Gonzalez-Porque;
E-mail: pgonzalez.hrc@salud.madrid.org
British Journal of Cancer (2003) 88, 940–943


























To test for the effect of LG on chemically induced skin tumours, we
have used the two-stage carcinogenesis model (Segal et al, 1978)
consisting in the single application of the carcinogen DMBA
followed by repetitive applications of the noncarcinogen promoter
PMA. We have slightly modified the published procedure by
substituting the solvent currently used (acetone) for a mixture of
dimethylsulphoxide/glycerol (1:1). This results in an easier
application and better spreading of the compounds on the mouse
skin and avoids the drawback of itching, uneasiness, and sore
formation in mice because of the delipidisation produced by the
continuous use of acetone. Consequently, mice are easier to handle
and are less aggressive. Also, this change does not affect the growth
of tumours since more than 90% of mice developed papillomas.
Table 1 summarises the results obtained in two types of
experiments. In one of them we investigated the effect that
increasing amounts of LG added together with the PMA solution
have on the prevention of tumour formation. In the other, we
studied the effect that topical application of an LG solution has on
already established tumours. In both cases, partial inhibition (i.e.
tumour size, number of papillomas, etc.) was not considered. Only
those mice in which there is complete prevention of tumour
formation or total remission of established tumours are recorded
in the table. The term ‘full remission’ (arbitrarily defined) refers to
those cases in which no papillomas were visually present after 8
weeks of treatment with LG and that if left untreated for a period of
up to 3 months they did not exhibit the growth of new papillomas.
In both series there is a clear dose–response relation, although the
amounts of LG needed for the prevention of tumour formation are
roughly 10 times lower than those needed for attaining full
regression of established tumours. Figure 1 shows the effect that
topical application of the solution of LG has on the regression of
tumours. Time 0 is the time at which treatment was installed (all
tumours had a developing time, under standard conditions, of
around 8 weeks). The treatment was evaluated after 4 and 8 weeks
of the initiation (see Materials and Methods). At a dose of 100mg
per application, the effect observed is only partial after 8 weeks
(Figure 1A). However, when the dose was increased to 250mg
(Figure 1B) or 500mg (Figure 1C), full remission was reached, in
most cases, after the same period of time. In all cases, it was
noticeable that during the treatment, tumours changed in size
and shape, passing from a smoother surface at the beginning
to a cauliflower-like surface with multiple indentations and
pedunculations which later fall without bleeding. However, the
surrounding nontumoral tissue is not affected by the treatment.
Indeed, the application of the highest dose (500mg) on healthy
mice does not produce any effect during the same period of time
(Figure 1D).
To analyse the anatomopathological characteristics of the
tumours undergoing LG treatment, mice were killed under
anaesthesia after different periods of time. Figure 2A shows the
normal skin, without significant lesions, of a healthy mouse. The
untreated tumoral mass induced by DMBA and PMA shows an
exophytic squamous lesion with a central core. The epidermal
surface presents orthokeratotic hyperkeratosis with clumps of red
cells and neutrophils. The tumour infiltrates the superficial dermis,
and marked nuclear atypia and frequent mitosis are also found
(Figure 2B). The characteristics of the tumoral mass after 4 weeks
of treatment with LG show features similar to the untreated
tumour. However, an increase in the number of apoptotic cells was
found (Figure 2C). The residual lesion after 8 weeks of LG
treatment (the tumoral mass has already disappeared) shows a
deep ulcer penetrating the muscular layer and granulation tissue at
the base. Also there is reactive hyperplasia of the epidermal
borders of the ulcer (Figure 2D). Finally, the treatment with LG on
healthy mice (analogue to Figure 1D) does not produce significant
alterations on the skin (Figure 2E).
As a complement or substitution of the traditional armamentar-
ium against tumoral growth and chemoprevention, based mainly
in cytotoxic chemotherapy, because of its toxicity, new approaches
dealing with the manipulation of signal transduction pathways
have been the centre of research during the last years. Protein
tyrosine phosphorylation is an early and key step activated by
receptor and nonreceptor PTKs which have been implicated in
carcinogenesis, tumour progression and metastasis when their
activities are not properly regulated (Kolibaba and Druker, 1997;
Porter and Vaillancourt, 1998; Blume-Jensen and Hunter, 2001).
An intensive search for inhibitors of these enzymes has proven to
be fruitful and some of these compounds are already at the
preclinical and clinical stages (Levitt and Koty, 1999). One would
expect that competitive inhibitors towards the tyrosine (acceptor
substrate) could be more efficient than inhibitors towards ATP
(donor substrate) because of the high intracellular ATP concen-
tration (in the mM range). However, most of the current strategies
are designed to inhibit the ATP binding by specific PTKs which are
overexpressed in certain tumours (i.e. imatinib mesylate (formerly
Figure 1 Effect of different doses of LG on the regression of
DMBA+PMA induced tumours. (A) 100mg, (B) 250mg, (C) 500mg and
(D) 500mg on healthy skin.
Table 1 Effect of different doses of LG on the prevention of tumour





Group LG 2.5 LG 10 LG 50 LG 100 LG 250 LG 500
Sex
Male 1/4 2/4 4/4 0/2 2/4 3/3
Female 0/4 2/4 3/4 0/3 2/4 2/4
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sSTI571) for Bcr-Abl in chronic myeloid leukaemia (Thiesing et al,
2000); ZD1839 (Iressa) for epidermal growth factor receptor
(Albanell et al, 2002) or WHI-PI 131 for Janus 3 kinase in acute
lymphobastic leukaemia (Uckun et al, 1999), among others).
However, sometimes the aberrant PTK is not identified or the
growth of the tumour may depend on the concerted action or
partial contribution of several PTKs. In such cases, the use of a
general nonspecific PTK inhibitor would be worthwhile consider-
ing. It may be argued that these kinds of inhibitors might have a
significant effect on normal cells as well. Nevertheless, the activity
of PTKs in normal cells is usually in the ‘off’ state, which is
switched to the ‘on’ state by means of specific ligand, activation of
transduction cascades, aberrant overexpression of the oncogenic
protein or expression of a mutant protein that escapes the tight
regulation of these enzymes. In our opinion, the use of LG (or
other alkyl gallates) as one of such inhibitors could be worth
investigating considering the following.
First, LG inhibits PTKs in whole cells, crude extracts and
purified form (PTK c-Src) without inhibiting serine/threonine
kinases (Palacios et al, 2002) and are not affected by high ATP
concentrations. This compound and other gallic acid derivatives
are able to induce apoptosis in tumoral cell lines showing
selectivity for rapidly growing cells (resting lymphocytes can
stand much higher concentrations than mitogen-stimulated
lymphocytes (Serrano et al, 1998).
Second, as shown in this report, LG is able to prevent the tumour
formation of skin tumours induced by DMBA and PMA in mice
and is able to induce full regression after topical application, on
already established tumours.
Third, because of their low toxicity, alkyl gallates have been
widely used as food additive antioxidants for over 50 years. Thus,
much of the work on their metabolism, toxicological effect and
pharmacokinetic studies has already been performed. Long-term
toxicity studies in rats and mice have shown that no effects were
observed at doses as high as 1000mgkg
 1 feed. In 1976, the FAO/
WHO Joint Expert Committee on Food Additives (JECFA)
established an acceptable daily intake (ADI) for man of
0.2mgkg
 1 body weight as a sum of propyl, octyl and LG (Van
der Heijden et al, 1986).
Also, their simple chemical structures and availability in
unlimited amounts at a very low commercial cost are important
aspects to consider.
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